Cotadutide

Trial

ClassDual agonist

Typical routes in papersDaily SC in many trial arms

Half-life contextDaily-class in early programs

EvidencePhase 2 metabolic / NASH

What it is

Cotadutide is an older dual GLP-1/glucagon agonist from the AstraZeneca line, studied in obesity, diabetes, and NASH.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

Same benefit theme as other duals: eat less and spend more energy.
Useful as background reading when someone asks how we got to survodutide and mazdutide.
Development status can change; this page is a mechanism archive.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

Oxyntomodulin-mimetic co-agonism at GLP-1R and GCGR.

Possible side effects / caveats

GI effects and glucagon-related metabolic shifts.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Trial examples	100–300 mcg class daily in some papers	Daily SC	Historical trial logic only

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.